Omaha, NE (PRWEB) February 26, 2005
SkinCeuticals, the company known for introducing the use of topical Vitamin C, has released a new topical antioxidant containing vitamin C, vitamin E and 0.5% ferulic acid. The company states that it has up to 8 times the photoprotection against oxidative stress (pollution and photoaging) and was impressed by the performance and potential of this new product. SkinCeuticals has presented studies to back up claims it is better than idebenone, another antioxidant used in the product Prevage.
Dr. Joel Schlessinger was one of only 12 dermatologists to be present at the introduction of C E Ferulic Serum, at the recent American Academy of Dermatology meeting in New Orleans. He questioned at length Dr. Sheldon Pinnell, the lead researcher for this product and Professor Emeritus at Duke University. ÂThis product excites me in that its studies were performed in real-life situations with the actual product rather than with different formulations and in mainly simulated situations as with other formulations,Â states Dr. Schlessinger, Board Certified Dermatologist and President of LovelySkin.com.
ÂOn our website we sell over 3000 products, so we need to be attentive to which products have the best science behind them and which provide the best chances for our customers to get a good result. We definitely like the chances for this new product C E Ferulic Serum. I honestly didnÂt expect to see such impressive results, but I canÂt dispute the science behind this exciting new antioxidant. Additionally, I like the fact that it is paraben-free and seems to be less irritating than many antioxidants. Time will tell, but this one seems to be a keeper,Â says Schlessinger.
Joel Schlessinger, M.D., President of LovelySkin.com, a Board Certified Dermatologist and Board Certified General Cosmetic Surgeon, is internationally known for his work in cosmetic dermatology and research in dermatology. Please call Sarah McCool for more information or if you wish to reach Dr. Schlessinger. Note that Dr. Schlessinger has no financial interest in this company.